RENB Key Statistics, Chart & Performance
The current stock price of RENB is 1.42 USD. In the past month the price decreased by -37.58%. In the past year, price decreased by -70.98%.
RENB Latest News, Press Relases and Analysis
RENB Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.6 | 394.11B | ||
| AMGN | AMGEN INC | 14.35 | 169.00B | ||
| GILD | GILEAD SCIENCES INC | 14.57 | 148.09B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 25.17 | 110.88B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.39 | 72.79B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 814.14 | 54.85B | ||
| INSM | INSMED INC | N/A | 41.41B | ||
| NTRA | NATERA INC | N/A | 32.51B | ||
| BIIB | BIOGEN INC | 10.5 | 25.80B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.05 | 20.51B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.21B | ||
| INCY | INCYTE CORP | 14.82 | 18.68B |
Related stock screener links
About RENB
Company Profile
Renovaro, Inc. is a pre-clinical stage biotechnology company, which engages in the development of genetically modified cellular and immune-therapy technologies used for the treatment of infectious diseases and cancer. The company is headquartered in Los Angeles, California and currently employs 25 full-time employees. The company went IPO on 2014-11-18. The firm is engaged in harnessing advanced computational biology and AI/machine learning to accelerate drug discovery, diagnostics and strengthen biosecurity capabilities. From high-resolution phenotyping to predictive disease modeling, the Company is pioneering a new era of precision diagnostics-where early detection, patient stratification, and therapeutic targeting converge into a single, adaptive platform. These are designed to transform clinical decision-making, reduce time-to-treatment, and unlock previously inaccessible insights from biological data. Its proprietary platforms in translational analytics, in vivo modeling, and machine vision-accelerating biomarker discovery and therapeutic development in precision neurology and infectious disease.
Company Info
LUNAI BIOWORKS INC
2080 Century Park East, Suite 906
Los Angeles CALIFORNIA US
Employees: 25
Phone: 14539179840
LUNAI BIOWORKS INC / RENB FAQ
What does RENB do?
Renovaro, Inc. is a pre-clinical stage biotechnology company, which engages in the development of genetically modified cellular and immune-therapy technologies used for the treatment of infectious diseases and cancer. The company is headquartered in Los Angeles, California and currently employs 25 full-time employees. The company went IPO on 2014-11-18. The firm is engaged in harnessing advanced computational biology and AI/machine learning to accelerate drug discovery, diagnostics and strengthen biosecurity capabilities. From high-resolution phenotyping to predictive disease modeling, the Company is pioneering a new era of precision diagnostics-where early detection, patient stratification, and therapeutic targeting converge into a single, adaptive platform. These are designed to transform clinical decision-making, reduce time-to-treatment, and unlock previously inaccessible insights from biological data. Its proprietary platforms in translational analytics, in vivo modeling, and machine vision-accelerating biomarker discovery and therapeutic development in precision neurology and infectious disease.
What is the current price of RENB stock?
The current stock price of RENB is 1.42 USD. The price increased by 12.16% in the last trading session.
What is the dividend status of LUNAI BIOWORKS INC?
RENB does not pay a dividend.
What is the ChartMill technical and fundamental rating of RENB stock?
RENB has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
Should I buy RENB stock?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on RENB.
What is LUNAI BIOWORKS INC worth?
LUNAI BIOWORKS INC (RENB) has a market capitalization of 327.92M USD. This makes RENB a Small Cap stock.
RENB Technical Analysis
RENB Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to RENB. While RENB seems to be doing ok healthwise, there are quite some concerns on its profitability.
RENB Financial Highlights
Over the last trailing twelve months RENB reported a non-GAAP Earnings per Share(EPS) of -0.44. The EPS increased by 59.96% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -57.15% | ||
| ROE | -76.11% | ||
| Debt/Equity | 0 |